Skip to main content
. 2017 Mar 14;114(13):3497–3502. doi: 10.1073/pnas.1702663114

Fig. 4.

Fig. 4.

Stauprimide inhibits tumor growth in xenograft tumor models. (A) Tumor volume measurement of RXF 393 cells injected s.c. into NOD/SCID mice and treated with stauprimide (50 mg/kg, once per day) or with vehicle [75% (vol/vol) PEG300; 25% (vol/vol) D5W], n = 10/group. (B) Immunohistochemistry staining of tumor samples using anti-MYC antibody at the end of the dosing period of A. (Scale bars: 100 μm.) (C) qRT-PCR analysis of human MYC mRNA in tumor samples at the end of the dosing period of A; mRNA abundance was normalized to human GAPDH. (D) Tumor volume measurement of CAKI-1 cells injected s.c. into NOD/SCID mice treated with stauprimide (50 mg/kg, once per day) or with vehicle [75% (vol/vol) PEG300; 25% (vol/vol) D5W], n = 5/group. (E) Fluorescent immunostaining of tumor samples using anti-MYC antibody at the end of dosing period of D. (Scale bars: 100 μm.) Arrowheads in A and D indicate the start of dosing. All data are presented as mean ± SD; statistical analyses were carried out using t test, *P < 0.05, **P < 0.01, ***P < 0.001.